bibapublishing

140 POSTS 0 COMMENTS

VeinCLEAR catheter shows short-term success of venous closures during radiofrequency ablation

A study conducted at St Thomas’ Hospital, London, UK, indicates that the VeinCLEAR catheter (RF Medical) produces good results when used in radiofrequency ablation...

Surfacer Inside-Out (Bluegrass Vascular Technologies) successfully used in first clinical case

The Surfacer Inside-Out access catheter system (Bluegrass Vascular Technologies) has been successfully used in its first clinical case. The patient in question was facing...

EVRF system trial shows 96.8% complete occlusion at three years

“EVRF (F Care Systems) saphenous ablation is a safe and painless procedure for the treatment of the greater saphenous vein and/or small saphenous vein,” according to recently released data. The authors, led by Attila Szabo, VP-Med Health and Education Centre, Budapest, Hungary, write that “high patient acceptance and minimal postoperative discomfort allows a quick return to work and normal life for patients.”

EVRF is a monopolar radiofrequency ablation system for endothermal treatment of small, midsize and large veins. “Endovenous procedures are far less invasive than surgery and have lower complication rates,” the authors write. “The procedure is well tolerated by the patients, and it produces good cosmetic results. Excellent clinical results are seen at four to five years, and the long-term efficacy of the procedure in now known with 10 years of experience.”


Szabo and colleagues evaluated the effectiveness of EVRF treatment and analysed the three-year results of using the device for endovenous radiofrequency ablation and spider vein treatments from July 2011 to March 2015 to treat 751 saphenous reflux and varicosity patients.


Radiofrequency ablation using the EVRF CR45i catheter was performed on 751 limbs (628 greater saphenous vein, 102 small saphenous vein and 21 for both). Complete occlusion was found in 743 of 751 cases (99%) at one month. At one-year follow-up, 15 of 530 patients showed recanalisation longer than 5cm (97.2% one-year occlusion) without clinical symptoms. The three-year occlusion rate was 96.6% (two of 59 patients had an open vein segment). At one-year follow-up the investigators evaluated the postoperative pain reported by the patients on a visual analogue scale (2.4 preoperatively, 1.2, 0.4 and 0.1 at one week, one month and one year postoperatively, respectively) and Venous Clinical Severity Scores (7.7, 3.9 and 1.8 before surgery, at one month and at one year, respectively). The average patient satisfaction was 99% at one year. There were no cases of deep vein thrombosis, skin burns, neuritis or bleeding. “Minimal” bruising was observed at the treatment site of the tributaries in some cases and four patients had mild inflammation which was treated conventionally.


For smaller veins, more than 5,000 treatment sessions for teleangiectasias and spider veins on the face and lower limbs were completed. The authors used radiofrequency treatment or combined the treatment with liquid sclerotherapy. Facial recovery rate was 100% and lower limb recovery rate was 82% on average. The treatments were “well tolerated—although the pain level always depends on the patients’ current psychic status—and the patient satisfaction rate was high,” the authors report.


Szabo and colleagues suggest that “EVRF is appropriate for the treatment of teleangiectasias, reticular veins with the hand piece and K3i or K6i needles (face or lower leg), small varicose veins or tributaries 2–5mm with the hand catheters and for saphenous truncs and perforators 4–15mm in diameter with the CR45i catheter.”


“The procedure, under local tumescent anaesthesia, is simple and the disposable devices are easy to use. The EVRF hand piece with K3i and K6i needles proved to be useful in teleangiectasia treatment, with excellent results,” Szabo et al conclude. “This radiofrequency procedure is also suitable for combination with liquid or foam sclerotherapy.”

First patients enrolled in RE-COVERY DVT/PE global observational study on management...

Boehringer Ingelheim has announced the enrolment of the first patient in RE-COVERY DVT/PE, a global observational study on the management of deep vein thrombosis...

FDA proposes ban on most powdered medical gloves

The US Food and Drug Administration has announced a proposal to ban most powdered gloves in the USA. While use of these gloves is...

Hybrid operative thrombectomy is non-inferior to percutaneous techniques for acute iliofemoral...

Hybrid operative thrombectomy achieves complete thrombus resolution in one operating room trip which results in reduced length of stay, bleeding complications and transfusions when...

Authorisation and reimbursement for radiofrequency and endovenous laser ablation across Europe

A few months ago a discussion on the LinkedIn page of the American College of Phlebology caught my attention: “Medicare: maximum four endovenous laser...

A novel method of oedema fluid drainage in obstructive lymphoedema

According to the World Health Organization, around 300 million people are affected by the pathological oedema of limbs. Lymphoedema is caused by partial or...

Saphenous pulsation on duplex ultrasound is a marker of severe chronic...

Saphenous pulsation is the cyclical impulse of antegrade flow observed on colour duplex ultrasound after prolonged standing. It is a common observation in patients...

AngioDynamics and Merz North America establish multi-year relationship to market Asclera...

AngioDynamics has signed an agreement with Merz North America, a US affiliate of the global Merz Pharma Group, to serve as the exclusive distributor of Asclera (polidocanol) injection...

When to use intervention for deep venous thrombosis and pulmonary embolism

At the 2016 Leipzig Interventional Course meeting (LINC; 26–29 January, Leipzig, Germany), Michael R Jaff, Boston, USA, discussed the challenges facing intervention for deep...

FDA confirms Robert Califf as new commissioner

The US Food and Drug Administration (FDA) has confirmed the appointment of Robert Califf as its 22nd commissioner, following a US Senate vote of 88...

ArtVentive announce enrolment in OCCLUDE post-market study of the EOS embolisation...

ArtVentive Medical has announced enrolment in the ongoing OCCLUDE post-market surveillance study. This study aims to further the use of the EOS endoluminal occlusion...

“We need to find the optimal stent configuration for venous disease”

Rick De Graaf, Department of Radiology, Maastricht University Medical Centre, Maastricht, The Netherlands, presented the results of the first comparative study of four dedicated...

Patient enrolment begins for PRESERVE study of retrievable inferior vena cava...

Researchers have activated the first 10 medical sites and enrolled the first nine patients in a study that will determine the safety and effectiveness...

AMPLIFY data indicate Eliquis (apixaban) is comparable to conventional therapy in...

Bristol-Myers Squibb and Pfizer have announced results from a post-hoc early time course subanalysis of the phase 3 AMPLIFY (Apixaban for the initial management of...

Low rates of major bleeding seen in pivotal trial of rivaroxaban...

Bayer and its development partner Janssen Pharmaceuticals presented results from two real world studies—the non-interventional XALIA study in patients with deep vein thrombosis (DVT)...

New European code says no to direct sponsorship of physicians to...

The European Diagnostics Manufacturers Association (EDMA) and the European Medical Technology Industry (Eucomed) have approved a new joint code of conduct that stipulates that,...

We “still await” the ideal venous stent, despite rapid development in...

By Athanasios D Giannoukas Today, venous stenting plays an important role in the treatment of deep venous pathologies. The current indications for its use include acute...

New clinical prediction model can help identify high risk of venous...

According to new a study published in PLOS Medicine, a new clinical model can help predict the risk of venous thromboembolism (VTE) among patients with...

VenaSeal closure system launched in the USA

Medtronic’s VenaSeal closure system has been granted pre-market approval (PMA) from the US Food and Drug Administration (FDA) for the treatment of symptomatic venous...

Catheter-directed thrombolysis for pulmonary embolism in the paediatric population

Peter H Lin   Pulmonary embolism in children is a potentially lethal condition and yet is a vastly understudied arena. Autopsy studies show a higher prevalence...

Lawrence Livermore National Lab and Near Infrared Imaging release Vein-Eye camera

The City University of New York (CUNY), Lawrence Livermore National Laboratory, and Near Infrared Imaging, have released the “Vein-Eye” camera. The Vein-Eye provides enhanced...

A new modality in vein treatment: Percutaneous valvuloplasty by interventional injection...

By Johann Chris Ragg  Patients with saphenous insufficiency can undergo valve zone shaping instead of destructive methods by surgical removal or endovenous closure, says Johann...

Dedicated endovenous stents effective to relieve outflow obstruction at one year

Dedicated venous stents can be effectively used to relieve outflow obstruction at one year following thrombotic disease in both the acute and chronic setting,...

NICE recommends once-daily Lixiana (edoxaban) to treat and prevent adult recurrent...

The National Institute for Health and Care Excellence (NICE), the medicines cost-effectiveness body for England and Wales, has recommended a new treatment to help...

Real world ETNA registries of new once-daily edoxaban commence in Europe

The first patient has been enrolled in ETNA-AF-Europe (Edoxaban treatment in routine clinical practice – atrial fibrillation – Europe), and ETNA-VTE-Europe (Edoxaban treatment in...

Cancer-associated thrombosis patients 35% less likely to experience thromboembolism when treated...

Results of the landmark CATCH (Comparison of Acute Treatments in Cancer Haemostasis) study were published in The Journal of American Medical Association (JAMA), comparing innohep (tinzaparin),...

Health Canada approves polidocanol injectable foam for patients with varicose veins

BTG announced on 6 August 2015 that Health Canada has issued a notice of compliance approving polidocanol injectable foam (Varithena, BTG) for the treatment...

Robotic vena cava surgery for tumour and filter removal

By Samuel Money Open vena caval surgery is rare. It is mainly performed for oncological indications when the inferior vena cava is involved by an...

Interview with Ian Franklin at CX 2015: New venous technologies

Ian Franklin, a member of the CX Programme Organising Board and director of the CX Venous Workshop, speaks about new technologies for the treatment...

Spiral saphenous vein reconstruction of the infected aorta: a strategy to...

Jan Heyligers and Patrick Vriens, Tilburg, The Netherlands, write about a technique using the great saphenous vein for the reconstruction of an infected aorta....

NICE publishes final guidance on the use of Eliquis (apixaban) to...

Bristol-Myers Squibb and Pfizer have announced that the National Institute for Health and Care Excellence (NICE) has published final guidance recommending the use of...

Edward Diethrich speaks about the impact of radiation on his health

This video tells the story of one of the world’s most prominent heart surgeons, Edward Diethrich, and the career-altering health issues he has faced...

A record-breaking week for the CX Venous Workshop

The second day of the CX Venous Workshop was held yesterday on the Upper Level of the Gallery, rounding off a busy week in...

CX Venous Workshop draws in the crowds

Yesterday saw the beginning of the two-day CX Venous Workshop, in which delegates can enjoy expert demonstrations of a selection of the most interesting...

Edoxaban approved for prevention of stroke and systemic embolism in non-valvular...

Daiichi Sankyo has announced that Swissmedic, the regulatory authority of Switzerland, has granted approval of Lixiana (edoxaban), an oral, once-daily selective factor Xa inhibitor, for...

Preliminary data suggest VenaTech convertible filter is a safe and effective...

Early data from a multicentre, single-arm study that set out to evaluate the safety and effectiveness of a novel approach to inferior vena cava...

Intrinsic Imaging awarded interventional medical device trial for prevention of pulmonary...

Intrinsic Imaging has been awarded a clinical trial to study an interventional medical device designed for the prevention of pulmonary emboli. Throughout this trial, Intrinsic...

New varicose vein treatment available in Europe

biolas has announced the launch of its VariClose vein sealing systems in Europe. VariClose is a new technique by which an incompetent saphenous vein is...

FDA classifies Covidien field action for Trellis-6 and Trellis-8 systems as...

Medtronic announced today that a previously communicated global voluntary recall to address an issue with certain lots of its Trellis-6 and Trellis-8 peripheral infusion...

FDA approves Savaysa for reduction of stroke risk in non-valvular atrial...

The US Food and Drug Administration (FDA) has approved Daiichi Sankyo’s Savaysa (edoxaban), an oral, once-daily selective factor Xa inhibitor, to reduce the risk...

What the vascular specialist must know about echo for pulmonary embolism

By David Dudzinski Transthoracic echocardiography offers real-time information that assists vascular specialists in the diagnostic and prognostic evaluation of acute pulmonary embolism. Specific roles of...

For doctors, social media should be like taking medicine—you do not...

By Ido Weinberg @Angiologist   The Merriam-Webster dictionary defines social media as “forms of electronic communication (as websites for social networking and microblogging) through which users...

Secondary analysis of AMPLIFY-EXT examining predictors of hospitalisation presented at ESC...

Bristol-Myers Squibb and Pfizer have announced results of a pre-specified secondary analysis of the Eliquis phase 3 AMPLIFY-EXT trial (Apixaban after the initial management...

Is all heat the same and does catheter design matter?

By Mark S Whiteley Since the NICE (National Institute for Health and Care Excellence) guidelines for the treatment of varicose veins was published in July...

First varicose vein patient treated with FDA-approved Varithena (polidocanol injectable foam)...

BTG International has announced that the first varicose vein patient has been treated with Varithena (polidocanol injectable foam), the only FDA-approved foam for the treatment...

European Commission approves Eliquis (apixaban) for treatment of deep vein thrombosis...

Bristol‐Myers Squibb Company and Pfizer have announced that the European Commission has approved Eliquis (apixaban) for the treatment of deep vein thrombosis and pulmonary...

More bleeding with catheter-directed thrombolysis than with standard anticoagulation in deep...

A study published in the Journal of the American Medical Association (JAMA) has found no difference in mortality rates between deep vein thrombosis patients...

FDA IDE approval for Veniti Vici venous stent system

Veniti has announced that it has received approval from the United States Food and Drug Administration (FDA) for an Investigational Device Exemption (IDE) to...

Multicentre study evaluates method to improve retrieval rate of inferior vena...

The Heart and Vascular Outcomes Research Institute (HVORI) is collaborating with a number of medical centres to launch the iRetrieve study aimed to improve...

Covidien launches next generation Trellis peripheral infusion system

Covidien has announced the commercial launch of its next generation Trellis peripheral infusion system. The redesigned system continues to be the only pharmacomechanical thrombolysis device that enables...

Eliquis (apixaban) receives CHMP positive opinion for the treatment of deep...

Bristol-Myers Squibb Company and Pfizer have announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has...

EKOS initiates study in patients with chronic deep vein thrombosis and...

EKOS Corporation has announced the start of patient enrolment for the Accelerated thrombolysis for post-thrombotic syndrome using the EkoSonic endovascular system (ACCESS PTS) study. The...

Pradaxa gains EU approval

Boehringer Ingelheim has announced that Pradaxa (dabigatran etexilate) has been approved by the European Commission for the treatment and prevention of recurrence of deep...

Cook Medical begins two studies on inferior vena cava filters

Cook Medical is engaged in two clinical studies that will provide additional data on the safety and effectiveness of inferior vena cava filters. The first...

Pelvic vein reflux could cause haemorrhoids, study suggests

Women with significant pelvic vein incompetence are likely to have haemorrhoids, which could suggest a causal link, according to research from a varicose vein...

Evidence for deep venous reconstruction is “extremely weak”

Stephen Black, St George’s Hospital, London, UK, told delegates at the Charing Cross Symposium (5–8 April 2014, London, UK) that most of the evidence...

FDA approves Pradaxa for treatment of deep venous thrombosis and pulmonary...

Boehringer Ingelheim Pharmaceuticals announced that the US Food and Drug Administration (FDA) has approved Pradaxa (dabigatran etexilate mesylate) for the treatment of deep venous...

Delegates benefit from hands-on training and learning at the CX Office-based...

At the CX Office-based Vein Practice Course, delegates were granted the unique opportunity to view demonstrations and try office-based venous devices and procedures with...

Edoxaban evaluated in two subgroup analyses of East Asian patients from...

Daiichi Sankyo announced late-breaking data from two pre-specified subgroup analyses of East Asian patients with non-valvular atrial fibrillation or venous thromboembolism enrolled in two...

For the first time, Charing Cross hosts three days of venous...

Recognising that new technologies and techniques are revolutionising how venous disorders are treated, in 2014, for the first time, the Charing Cross Symposium (5–8...

Veniti announces first uses of Veniti Vici Venous Stent System

Veniti announced on 23 January 2014 that patients in the European Union (EU) were successfully treated for symptomatic venous outflow obstruction of the lower...

ULTIMA trial results published in Circulation

EKOS Corporation announced on 20 January 2014 the publication of the results of its ULTIMA (Ultrasound accelerated thrombolysis of pulmonary embolism) trial in Circulation....

Option Elite retrievable vena cava filter receives FDA clearance for a...

Argon Medical Devices announced that it has received clearance from the US Food and Drug Administration to begin marketing the Option Elite retrievable inferior...

Sapheon submits second module of PMA application for VenaSeal Sapheon Closure...

Sapheon has announced that it has submitted the second module of the pre-market approval (PMA) application for the VenaSeal Sapheon Closure System to the...

New drug application for edoxaban submitted in Japan

Daiichi Sankyo is seeking approval in Japan for edoxaban in new indications for non-valvular atrial fibrillation and symptomatic venous thromboembolism. Daiichi Sankyo has announced that it has...

Phase III study of dabigatran meets primary endpoint for six-month treatment...

Boehringer Ingelheim has announced results from the RE-COVER II study evaluating dabigatran compared to warfarin in patients diagnosed with acute deep vein thrombosis and/or...

Lowell S Kabnick

Lowell S Kabnick, associate professor, NYU Langone Medical Center, New York, USA, has worked to develop minimally invasive systems for the treatment of varicose...

FDA approves polidocanol injectable foam for varicose veins

BTG has announced that the FDA has approved polidocanol injectable foam (Varithena) for the treatment of patients with incompetent veins and visible varicosities of...

Increasing filter retrieval rates should be a priority

By Brian G DeRubertis   Surgical caval interruption for prevention of fatal pulmonary embolisation had been performed since the 1950s, though the modern era of pulmonary...

New rotational pharmacomechanical thrombectomy device promising for deep vein thrombosis

A new rotational thrombectomy device is safe and effective in the treatment of acute and subacute deep vein thrombosis in a single session of...

Treating cutaneous ulcers with human skin wound dressings

Researchers from Universite Laval’s Faculty of Medicine and CHU de Quebec have shown that it is possible to treat venous ulcers unresponsive to conventional...

Screening can significantly reduce number of venous thromboembolism deaths

A UK national initiative to carry out mandatory screening of hospital patients for deep vein thrombosis has resulted in a “significant” reduction in death rates, experts...

LeMaitre Vascular acquires InaVein

LeMaitre Vascular has announced that it acquired the assets of InaVein for US$2.5mm, or 1.1X InaVein’s 2012 sales, and potential earn-out payments in 2014...

New anticoagulant edoxaban shows less bleeding than warfarin in Hokusai-VTE

Results from the Hokusai-VTE study presented at the European Society of Cardiology (ESC) congress have shown that the oral anticoagulant edoxaban was non-inferior to...

Sapheon completes enrolment in US pivotal study of VenaSeal

Sapheon announced on 9 September 2013 that it has completed enrolment in the US pivotal study of the VenaSeal Sapheon Closure System. According to...

Tactile Medical launches wound care product to treat venous leg ulcers

Tactile Medical has launched an ambulatory device for patients with chronic wounds. The ACTitouch Adaptive Compression Therapy system combines two proven therapies—intermittent and sustained...

Canadian study suggests no link between venous stenosis and multiple sclerosis

There is no evidence that impaired blood flow or blockage in the veins of the neck or head is involved in multiple sclerosis, says...

12-month data supports the use of super glue for varicose vein...

Haroun Gajraj, director of the The VeinCare Centre, Bristol, UK, speaks about using medical super glue for the treatment of varicose veins and superficial...

Thermocoagulation of the great saphenous vein with EVRF is safe and...

Thermocoagulation with a new endovenous radiofrequency system is a safe and efficient technique in the treatment of reflux of the great saphenous vein, according...

Offer less invasive treatments before surgery for varicose veins, says UK...

Surgery should only be offered to treat varicose veins if other less invasive treatments are unsuitable for patients, according to a guidance issued by...

No evidence to support placement of filters in patients undergoing bariatric...

A review of the literature suggests there is insufficient evidence to support the use of intravascular filters or augmented dosing of anticlotting medication in...

New segmental venous stent shows superior patency rates in occlusive disease

At CX35 (6–9 April, London, UK), Cees Wittens, Maastricht, The Netherlands, presented his experience with stents for deep vein occlusive disease. He told delegates...

Glue is a promising tool in the varicose vein occlusion armamentarium

Gerard Stansby, Newcastle, UK, told delegates at CX35 (6–9 April 2013, London, UK) that the use of glue in varicose veins in safe and...

NICE UK draft guidance recommends rivaroxaban for pulmonary embolism

The UK National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending rivaroxaban (Xarelto, Bayer Healthcare) as a clinically and...

Global clinical study initiated to determine safety and effectiveness of stent...

Cook Medical has launched the VIVO clinical research study to evaluate the safety and effectiveness of the Zilver Vena Venous Self-Expanding Stent in the...

Ultrasound-accelerated thrombolysis shows advantage over anticoagulation alone in submassive pulmonary embolism

Results of the ULTIMA pulmonary embolism trial comparing endovascular therapy to standard of care were presented at the American College of Cardiology meeting in...

Studies support benefit of dabigatran for prevention of recurrent deep vein...

The New England Journal of Medicine has published findings from the RE-MEDY and RE-SONATE trials investigating dabigatran etexilate (Pradaxa, Boehringer Ingelheim) in the long-term prevention...

“Filter or no filter” during percutaneous endovenous intervention for deep vein...

By Mohsen Sharifi Percutaneous endovenous intervention (PEVI) is increasingly being used in the treatment of massive lower extremity deep vein thrombosis. It utilises a variety...

ALN launches Vena Cava Filter with Hook in the USA

ALN (ALN Implants Chirurgicaux, France) announced the launching in the USA of its new ALN Vena Cava Filter with Hook, which recently received the...

Advances in drug therapy for the treatment of thrombophlebitis and pulmonary...

By Russell Samson Aspirin finds a role again Before the advent of more potent heparin, low molecular weight heparins and warfarin, aspirin was used extensively in the...

PREFER in VTE European registry enrols first patient

Daiichi Sankyo Europe announced the enrolment of the first patient into the PREFER in VTE (Prevention of thromboembolic events – European registry in venous...

Peter Gloviczki

Peter Gloviczki, professor of Surgery, College of Medicine, Mayo Clinic, Rochester, USA, is the president of the Society for Vascular Surgery (SVS) 2012–2013. Gloviczki,...

PEARL registry results suggest rheolytic thrombectomy combined with adjunctive therapy is...

The results of PEARL (Registry of AngioJet use in the peripheral vascular system), a phase II multicentre registry, led by Robert Lookstein, chief of...

Five-year results from the ClosureFast long-term European multicentre study announced

Covidien announced the five-year results of the ClosureFast Long-Term European Multi-Center Study in patients with chronic venous insufficiency in December. The ClosureFast study was...

Volcano Corporation to acquire Crux Biomedical

On 3 December, Volcano Corporation announced it has signed an agreement to acquire Crux Biomedical, developer of the Crux VCF System―an inferior vena cava...

European commission approves rivaroxaban for the treatment of pulmonary embolism and...

Rivaroxaban (Xarelto, Bayer HealthCare) has been approved by the European Commission for the treatment of pulmonary embolism (PE) and the prevention of recurrent deep...

ASPIRE trial shows 34% reduction in major vascular events with aspirin...

Low-dose aspirin prevents recurrent venous thromboembolism and major vascular events in patients with first unprovoked venous thromboembolism, results from the ASPIRE randomised controlled trial,...

FDA expands use of rivaroxaban to treat deep vein thrombosis or...

On 2 November, the US Food and Drug Administration (FDA) expanded the approved use of rivaroxaban (Xarelto) to include treating deep vein thrombosis (DVT)...

Rivaroxaban recommended for approval for pulmonary embolism in Europe

The European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of the oral anticoagulant rivaroxaban...

Computerised checklist offers best preventive strategy for venous thromboembolism

A computerised checklist system designed to help physicians identify and use the best methods of preventing potentially venous thromboembolism (VTE) in hospitalised trauma patients...

Cook Medical launches Zilver Vena Venous Self-Expanding Stent in Canada

Following Health Canada approval, Cook Medical announced the Canadian launch of the Zilver Vena Venous Self-Expanding Stent at the 2012 Annual Meeting of the...

UK’s NICE consults on new draft quality standard for management of...

On 3 October, the UK’ National Institute for Health and Clinical Excellence (NICE) opened a consultation on a new draft quality standard for the...

Genetics of venous disease

By David L Gillespie Varicose veins are a common condition affecting more than 25 million people in the United States. While the genetic basis of varicose...

Vascular Insights announces randomised clinical trial comparing VNUS Closure Fast with...

Vascular Insights has announced the start of a multicentre randomised clinical trial conducted by principal investigators Alun H Davies, professor of Vascular Surgery and...

Phase III study investigates cell-based therapy for venous leg ulcers

On 11 September 2012, Healthpoint Biotherapeutics announced the initiation of a phase III clinical trial investigating the efficacy of HP802-247 for the treatment of...

New developments in retrievable inferior vena cava filters reviewed

The new Crux inferior vena cava filter can be implanted and retrieved safely and shows a low rate of pulmonary embolism, Anthony J Comerota,...

94% closure rate of varicose veins after one year with VenaSeal...

Sapheon announced one year data in a 38-patient clinical study of the VenaSeal Sapheon Closure System, an advanced approach to the treatment of saphenous...

Radiofrequency ablation effective in the treatment of large diameter varicose veins...

Endovenous radiofrequency ablation is effective in the treatment of large diameter varicose veins irrespective of anatomical structure, according to a study presented by Andrey...

Study based on “real world” US database sheds light on inferior...

Emily A Wood, Division of Vascular Surgery, Stony Brook University Medical Center, USA, spoke at the European Venous Forum Annual Meeting (28–30 June, Florence,...

Tulip fibre shows reduced side-effects in great saphenous vein ablation

The use of a new fibre for endovenous laser ablation of the great saphenous vein results in equal occlusion rates as achieved with a...

FDA clears first ever bi-directionally retrievable vena cava filter from Crux...

The US Food and Drug Administration (FDA) has cleared Crux Biomedical’s inferior vena cava filter with bi-directional retrieval for the prevention of pulmonary embolism....

Ultrasound-accelerated catheter-directed thrombolysis of acute iliofemoral vein thrombosis remains safe

The use of ultrasound-accelerated catheter-directed thrombolysis to treat acute iliofemoral deep vein thrombosis continues to be feasible and safe, according to a study presented...

FDA grants priority review for rivaroxaban supplemental new drug application for...

The US Food and Drug Administration (FDA) has assigned a priority review designation to the supplemental new drug applications (sNDAs) filed on 2 May...

Covidien launches campaign to increase awareness of pregnancy-related blood clots

On 27 June 2012, Covidien announced the launch of  its “1 in 1,000” campaign to help educate women about the risk of pregnancy-related blood...

NICE clinical guideline set to save lives by improving the diagnosis...

New guidance published on 27 June 2012 by the UK National Institute for Health and Clinical Excellence (NICE) aims to reduce the current high...

Mechanochemical ablation shows 96% closure rate at two years

At two years, mechanochemical ablation (MOCA) is as efficacious as current endothermal techniques without the need of tumescent anaesthesia and is more effective than...

Angel Catheter is CE-marked

BiO2 Medical has announced that it has received CE mark approval for the Angel Catheter, a nitinol inferior vena cava (IVC) filter, permanently attached...

Satisfactory results with endovenous laser ablation 6.5 years after treatment

Michael Gough, Leeds General Infirmary, Leeds, UK, presented long-term follow-up after endovenous laser ablation for great saphenous varicose veins at the 34th Charing Cross...

Stryker launches Restep deep vein thrombosis compression sleeve

Stryker’s Sustainability Solutions division has announced the launch of Restep, a compression sleeve for deep vein thrombosis treatment. Restep provides hospitals with a single-source opportunity...

UK’s NICE encourages research on percutaneous venoplasty for multiple sclerosis

Final guidance from the UK’s National Institute for Health and Clinical Excellence (NICE), released on 28 March, encourages further research into percutaneous venoplasty, a...

Rivaroxaban shows comparable efficacy to standard of care for pulmonary embolism...

Results of the EINSTEIN-PE study have shown that the oral anticoagulant rivaroxaban (Xarelto, Janssen and Bayer Healthcare) was comparable to today’s standard of care...

Percutaneous endovenous intervention effective for upper extremity deep venous thrombosis

Mohsen Sharifi, adjunct associate professor of Medicine at A T Still University, Mesa, USA, presented new data demonstrating that percutaneous endovenous intervention (PEVI) is...

Recurrence after ablation for varicose veins associated with perforating veins

The majority of recurrences following thermal ablation for varicose veins are associated with perforating veins, results of the REVATA study have shown. The investigation...

Long-term outcomes of percutaneous mechanical thrombectomy for severe pulmonary embolism

Guering Eid-Lidt, Department of Interventional Cardiology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, spoke about long-term outcomes of percutaneous mechanical thrombectomy for...

FDA clears NeverTouch Direct Procedure Kit to treat varicose veins

The US Food and Drug Administration FDA has granted 510(k) clearance to AngioDynamics to market its NeverTouch Direct Procedure Kit for use with the...

Scottish Medicines Consortium accepts rivaroxaban for NHS use in two new...

The anticoagulant rivaroxaban (Bayer HealthCare, Xarelto) has been accepted by the Scottish Medicines Consortium (SMC) for use in eligible patients within NHS Scotland in...

Vascular Solutions launches reprocessing service for ClosureFAST catheter

Vascular Solutions announced that it is marketing a reprocessing service for the ClosureFAST radiofrequency ablation catheter in the United States. The ClosureFAST catheter, which...

Are inferior vena cava filters as good as we think in...

By Jörn Oliver Balzer Pulmonary embolism continues to be a major cause of morbidity and mortality in the United States. In most clinical situations, anticoagulation...

Crux Biomedical’s inferior vena cava filter receives CE mark

Crux Biomedical announced it has received CE mark approval for their inferior vena cava filter (IVCF) with bi-directional retrieval (BDR). The Crux Biomedical IVCF was...

One-year data of the Sapheon Closure system trial show positive results

Sapheon announced one year results in its first in-man safety trial of the Sapheon Closure system. At the one year mark, 100% of the...

Catheter-directed thrombolysis reduces risk of post-thrombotic syndrome in patients with DVT...

Researchers from Norway have found that additional treatment with catheter-directed thrombolysis (CDT), when compared to standard treatment of oral anticoagulation therapy and elastic compression...

Bluegrass Vascular Technologies begins first clinical study of the Surfacer Inside-Out...

Bluegrass Vascular Technologies has announced patient enrolment in the first clinical study of its Surfacer Inside-Out access catheter system, a proprietary system that allows...

Edoxaban significantly reduces risk of venous thromboembolism by half compared to...

On 12 December, Daiichi Sankyo announced the results of a pooled analysis showing that edoxaban, a direct oral once-daily Factor Xa inhibitor, significantly reduced...

Bioconvertible inferior vena cava filter could eliminate retrieval and complications

David Rosenthal, clinical professor of Surgery at the Medical College of Georgia, and chief of Vascular Surgery, Atlanta Medical Center, Atlanta, USA, presented data...

Charles McCollum

Charles McCollum, University of Manchester, UK, became consultant and senior lecturer in Surgery at the Charing Cross Hospital, London, UK, in 1983, aged 32....

DVT: risk factors, symptoms and prevention

https://youtu.be/ac_om5HCjvg

Will foam sclerotherapy win the office-based battle for the treatment of...

Here is a personal view by Roger Greenhalgh about the management of varicose veins. It comes from a vascular surgeon who has spent most...